Shuttle Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025
Shuttle Pharmaceuticals Holdings (Nasdaq: SHPH) has announced its participation in the Planet MicroCap Showcase: VEGAS 2025, scheduled for April 23, 2025, at 2:30 PM Pacific Time. Dr. Anatoly Dritschilo, Chairman and Chief Scientific Officer, will present updates on two key initiatives:
1. The ongoing Phase 2 trial of Ropidoxuridine and radiation therapy for glioblastoma patients
2. Developments at Shuttle Diagnostics subsidiary, focusing on pretreatment diagnostic blood tests and imaging agents for prostate cancer patients
The presentation will take place at the Paris Hotel & Casino in Las Vegas, with both in-person and webcast attendance options. The company, founded in 2012 by Georgetown University Medical Center faculty, focuses on improving outcomes for cancer patients through radiation therapy enhancement, developing radiation sensitizers to increase cure rates and improve survival rates.
Shuttle Pharmaceuticals Holdings (Nasdaq: SHPH) ha annunciato la sua partecipazione al Planet MicroCap Showcase: VEGAS 2025, previsto per il 23 aprile 2025 alle 14:30 ora del Pacifico. Il Dr. Anatoly Dritschilo, Presidente e Direttore Scientifico, presenterà aggiornamenti su due iniziative chiave:
1. La fase 2 in corso della sperimentazione di Ropidoxuridina e terapia radioterapica per pazienti con glioblastoma
2. Sviluppi presso la controllata Shuttle Diagnostics, focalizzati su test diagnostici ematici pre-trattamento e agenti di imaging per pazienti con cancro alla prostata
La presentazione si terrà al Paris Hotel & Casino di Las Vegas, con opzioni di partecipazione sia in presenza che in webcast. Fondata nel 2012 da docenti del Georgetown University Medical Center, l’azienda si concentra sul miglioramento dei risultati per i pazienti oncologici attraverso il potenziamento della radioterapia, sviluppando sensibilizzanti per aumentare i tassi di guarigione e migliorare la sopravvivenza.
Shuttle Pharmaceuticals Holdings (Nasdaq: SHPH) ha anunciado su participación en el Planet MicroCap Showcase: VEGAS 2025, programado para el 23 de abril de 2025 a las 2:30 PM hora del Pacífico. El Dr. Anatoly Dritschilo, Presidente y Director Científico, presentará actualizaciones sobre dos iniciativas clave:
1. El ensayo de fase 2 en curso de Ropidoxuridina y terapia de radiación para pacientes con glioblastoma
2. Avances en la subsidiaria Shuttle Diagnostics, centrados en pruebas diagnósticas sanguíneas previas al tratamiento y agentes de imagen para pacientes con cáncer de próstata
La presentación tendrá lugar en el Paris Hotel & Casino en Las Vegas, con opciones de asistencia presencial y por webcast. La empresa, fundada en 2012 por profesores del Georgetown University Medical Center, se enfoca en mejorar los resultados para pacientes con cáncer mediante la mejora de la radioterapia, desarrollando sensibilizadores para aumentar las tasas de curación y mejorar la supervivencia.
Shuttle Pharmaceuticals Holdings (나스닥: SHPH)는 2025년 4월 23일 태평양 표준시 오후 2시 30분에 예정된 Planet MicroCap Showcase: VEGAS 2025에 참여한다고 발표했습니다. 아나톨리 드리치실로 박사는 회장이자 최고 과학 책임자로서 두 가지 주요 이니셔티브에 대한 업데이트를 발표할 예정입니다:
1. 교모세포종 환자를 위한 Ropidoxuridine과 방사선 치료의 2상 임상 시험 진행 상황
2. 전립선암 환자를 위한 치료 전 진단 혈액 검사 및 영상 진단제에 중점을 둔 자회사 Shuttle Diagnostics의 개발 현황
발표는 라스베이거스의 Paris Hotel & Casino에서 진행되며, 현장 참석과 웹캐스트 참여 옵션이 제공됩니다. 2012년 조지타운 대학교 의과대학 교수진에 의해 설립된 이 회사는 방사선 치료 개선을 통해 암 환자의 치료 결과를 향상시키는 데 주력하며, 치료 효과를 높이고 생존율을 개선하기 위한 방사선 감작제 개발에 집중하고 있습니다.
Shuttle Pharmaceuticals Holdings (Nasdaq : SHPH) a annoncé sa participation au Planet MicroCap Showcase : VEGAS 2025, prévu le 23 avril 2025 à 14h30, heure du Pacifique. Le Dr Anatoly Dritschilo, président et directeur scientifique, présentera des mises à jour sur deux initiatives clés :
1. L’essai de phase 2 en cours de Ropidoxuridine et de radiothérapie pour les patients atteints de glioblastome
2. Les développements chez la filiale Shuttle Diagnostics, axés sur les tests sanguins diagnostiques pré-traitement et les agents d’imagerie pour les patients atteints de cancer de la prostate
La présentation aura lieu au Paris Hotel & Casino de Las Vegas, avec des options de participation en personne ou par webcast. Fondée en 2012 par des membres du corps professoral du Georgetown University Medical Center, la société se concentre sur l’amélioration des résultats pour les patients atteints de cancer grâce à l’amélioration de la radiothérapie, en développant des sensibilisateurs à la radiation pour augmenter les taux de guérison et améliorer la survie.
Shuttle Pharmaceuticals Holdings (Nasdaq: SHPH) hat seine Teilnahme an der Planet MicroCap Showcase: VEGAS 2025 angekündigt, die am 23. April 2025 um 14:30 Uhr Pazifischer Zeit stattfindet. Dr. Anatoly Dritschilo, Vorsitzender und Chief Scientific Officer, wird Updates zu zwei wichtigen Initiativen präsentieren:
1. Die laufende Phase-2-Studie von Ropidoxuridin und Strahlentherapie bei Patienten mit Glioblastom
2. Entwicklungen bei der Tochtergesellschaft Shuttle Diagnostics, die sich auf prätherapeutische diagnostische Bluttests und Bildgebungsagenten für Prostatakrebspatienten konzentriert
Die Präsentation findet im Paris Hotel & Casino in Las Vegas statt, mit Optionen zur Teilnahme vor Ort oder per Webcast. Das 2012 von Fakultätsmitgliedern des Georgetown University Medical Center gegründete Unternehmen konzentriert sich darauf, die Ergebnisse für Krebspatienten durch Verbesserung der Strahlentherapie zu optimieren, indem es Strahlensensibilisatoren entwickelt, um Heilungsraten zu erhöhen und die Überlebensraten zu verbessern.
- None.
- None.
Company to conduct 1x1 meetings on April 24, 2025
GAITHERSBURG, Md., April 21, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025, at 2:30 p.m. Pacific Time (5:30 p.m. Eastern Time). Anatoly Dritschilo, M.D., Chairman of the Board of Directors and Chief Scientific Officer of Shuttle Pharma, will be hosting the presentation and answering questions at the conclusion.
Dr. Dritschilo’s presentation will focus on providing an overview and update on the Company’s ongoing Phase 2 trial of Ropidoxuridine and RT for treatment of patients with glioblastoma as well as advancements being made in the Company’s Shuttle Diagnostics subsidiary which aims to develop pretreatment diagnostic blood tests and imaging agents for prostate cancer patients.
To access the live presentation, please use the following information:
Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub
Date: Wednesday, April 23, 2025
Time: 2:30 p.m. Pacific Time (5:30 p.m. Eastern Time)
Location: Track 3 – Chablis at the Paris Hotel & Casino in Las Vegas, NV
Webcast: https://event.summitcast.com/view/YNz6mnmEsXyrdRxb78w2nX/Js2DcQMoTdPkzijmn5bhuj
If you would like to schedule a 1x1 meeting with management, please contact your Planet MicroCap representative or the Company’s investor relations team at 1x1@lythampartners.com. 1x1 meetings will be scheduled and conducted in person at the conference venue: Paris Hotel & Casino in Las Vegas, NV
About Shuttle Pharmaceuticals
Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharma is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Our mission is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers, we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment or in combination with surgery, chemotherapy and immunotherapy. For more information, please visit our website at www.shuttlepharma.com.
Safe Harbor Statement
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements concerning the development of our company. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the “Risk Factors” section of Shuttle Pharma’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 26, 2025, as well other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, Shuttle Pharmaceuticals specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Shuttle Pharmaceuticals
Anatoly Dritschilo, M.D.
Chairman and Chief Scientific Officer
240-403-4212
info@shuttlepharma.com
Investor Contacts
Lytham Partners, LLC
Robert Blum
602-889-9700
shph@lythampartners.com
FAQ
What will Shuttle Pharmaceuticals (SHPH) present at the Planet MicroCap Showcase 2025?
How can investors attend Shuttle Pharmaceuticals' presentation at Planet MicroCap 2025?
What are the main focus areas of Shuttle Pharmaceuticals' (SHPH) cancer research?
What is the current development stage of SHPH's Ropidoxuridine treatment?
What diagnostic solutions is Shuttle Pharmaceuticals developing through its Diagnostics subsidiary?
